The Rare Treatment Accelerator is a global partnering programme that gives patient groups and Healx the opportunity to work together to quickly discover and develop repurposed treatments for rare diseases using AI. We have committed a total of $20 million over the next two years towards finding new treatments – investing up to the value of $1 million, in AI and drug discovery resources, per rare disease project.
Following the launch of the Rare Treatment Accelerator programme, we received a great amount of interest from patient groups worldwide. To help applicants better understand the Rare Treatment Accelerator collaboration model and the application process we hosted a webinar, co-presented by Dr Bruce Bloom (Chief Collaboration Officer) and Dr Anthony Hall (Chief Medical Officer).
During this 60-minute session, Bruce and Anthony talk through the following topics:
– An introduction to the Rare Treatment Accelerator: purpose, benefits and process
– The value of the information submitted
– How to complete and submit your application form
– Review of our FAQs
– Live Q&A session
You can watch the webinar recording below. We did our best to answer as many questions during the session, but if you have any additional ones for us please take a look at our FAQs section or submit them via email to email@example.com
About the Rare Treatment Accelerator
The Rare Treatment Accelerator is a partnering programme that offers rare disease patient groups and Healx the opportunity to work together to quickly discover and develop repurposed treatments for rare diseases using AI.
Healx and selected applicants will combine their AI technology, data, disease and drug discovery expertise to develop novel repurposed therapies and move them towards the clinic within an expected timeframe of 24 months – with Healx contributing up to the value of $1 million in AI and drug discovery resources per project. For more information, please visit: https://www.healx.io/rare-treatment-accelerator
About our speakers
Dr Bruce Bloom | Chief Collaboration Officer
Bruce is the founder and former CEO of Cures Within Reach, one of the leading global charities focused on drug repurposing. He has 30 years’ experience developing global clinical research collaborations – leading to 13 repurposed therapies delivered to patients. He is also either a board member or science advisor to over a dozen charities, philanthropies, academic institutions and biotechs.
Dr Anthony Hall | Chief Medical Officer
Tony is co-founder and trustee of the rare diseases patient group support charity, Findacure. He has 25 years of drug development experience – with 10 years working on rare diseases. Tony is also a member on the Scientific Advisory Board for Duchenne UK and co-editor of The Patient Group Handbook for rare diseases.